Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 08
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+15.82%
|
$35,000
$7.27 P/Share
|
Sep 07
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
495
-3.19%
|
$19,800
$40.0 P/Share
|
Sep 07
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
495
+3.09%
|
$2,970
$6.55 P/Share
|
Sep 07
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,375
-30.26%
|
$365,625
$39.71 P/Share
|
Sep 07
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+23.23%
|
$56,250
$6.55 P/Share
|
Aug 27
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
14,916
-90.84%
|
$522,060
$35.0 P/Share
|
Aug 27
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
14,916
+47.6%
|
$104,412
$7.8 P/Share
|
Aug 27
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.69%
|
$132,430
$34.58 P/Share
|
Aug 27
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
Aug 26
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-5.32%
|
$128,535
$33.89 P/Share
|
Aug 26
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
Aug 25
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-5.32%
|
$132,430
$34.09 P/Share
|
Aug 25
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
Aug 16
2021
|
Nitin Sood Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
97,213
+50.0%
|
-
|
Aug 11
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-16.58%
|
$330,000
$33.98 P/Share
|
Aug 11
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.04%
|
$60,000
$6.55 P/Share
|
Aug 10
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-18.79%
|
$175,000
$35.0 P/Share
|
Aug 10
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+15.82%
|
$30,000
$6.55 P/Share
|
Jul 21
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.69%
|
$144,115
$37.7 P/Share
|
Jul 21
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
Jul 20
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.69%
|
$144,115
$37.32 P/Share
|
Jul 20
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
Jul 19
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.69%
|
$144,115
$37.02 P/Share
|
Jul 19
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
Jul 19
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
SELL
Open market or private sale
|
Direct |
651
-6.64%
|
$23,436
$36.12 P/Share
|
Jul 19
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+6.22%
|
$14,322
$22.55 P/Share
|
Jul 14
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
2,500
-62.44%
|
$90,000
$36.8 P/Share
|
Jul 14
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+38.44%
|
$17,500
$7.8 P/Share
|
Jul 12
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
1,501
-0.09%
|
$57,038
$38.24 P/Share
|
Jul 08
2021
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,254
-3.94%
|
$81,144
$36.3 P/Share
|
Jul 07
2021
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
871
-1.5%
|
$33,969
$39.42 P/Share
|
Jul 07
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-17.26%
|
$380,000
$38.68 P/Share
|
Jul 07
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.04%
|
$60,000
$6.55 P/Share
|
Jul 06
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-31.64%
|
$380,000
$38.83 P/Share
|
Jul 06
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.04%
|
$60,000
$6.55 P/Share
|
Jun 30
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
4,167
-11.1%
|
$170,847
$41.74 P/Share
|
Jun 30
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
4,167
+7.23%
|
$62,505
$15.35 P/Share
|
Jun 18
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
SELL
Open market or private sale
|
Direct |
1,301
-12.44%
|
$50,739
$39.8 P/Share
|
Jun 18
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
BUY
Exercise of conversion of derivative security
|
Direct |
1,301
+11.06%
|
$28,622
$22.55 P/Share
|
Jun 17
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
SELL
Open market or private sale
|
Direct |
651
-6.64%
|
$26,040
$40.0 P/Share
|
Jun 17
2021
|
Jyoti Palaniappan SVP, Diagnostics, T-Detect |
BUY
Exercise of conversion of derivative security
|
Direct |
651
+6.22%
|
$14,322
$22.55 P/Share
|
Jun 17
2021
|
Michelle Renee Griffin Director |
SELL
Open market or private sale
|
Direct |
4,000
-72.67%
|
$160,000
$40.0 P/Share
|
Jun 17
2021
|
Michelle Renee Griffin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+42.09%
|
$28,000
$7.8 P/Share
|
Jun 17
2021
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
14,583
-20.06%
|
$583,320
$40.0 P/Share
|
Jun 17
2021
|
R Mark Adams Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,583
+16.71%
|
$408,324
$28.1 P/Share
|
Jun 17
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
4,166
-21.7%
|
$166,640
$40.0 P/Share
|
Jun 17
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
4,166
+7.23%
|
$62,490
$15.35 P/Share
|
Jun 17
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,255
-0.15%
|
$204,945
$39.15 P/Share
|
Jun 16
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
4,745
-0.27%
|
$180,310
$38.13 P/Share
|
Jun 15
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
20,000
-0.57%
|
$760,000
$38.73 P/Share
|